Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 701–800 of 1,000
Cyclic Naphthalene Diimide Dimer with a Strengthened Ability to Stabilize Dimeric G‐Quadruplex
Takeuchi, R., Zou, T., Wakahara, D., Nakano, Y., Sato, S., & Takenaka, S. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201901468 · Cited by 23
5′ C-rich telomeric overhangs are an outcome of rapid telomere truncation events
Oganesian, L., & Karlseder, J. (2013) · DNA repair · doi:10.1016/j.dnarep.2012.12.008 · Cited by 24
“However, a distinct telomerase-independent mechanism, termed ALT, is active in a subset of tumors [2].”
BackgroundTelomere maintenance in liquid crystalline chromosomes of dinoflagellates
Fojtová, M., Wong, J. T. Y., Dvořáčková, M., Yan, K. T. H., Sýkorová, E., & Fajkus, J. (2010) · Chromosoma · doi:10.1007/s00412-010-0272-y · Cited by 24
“Alternatively, these mechanisms can act as a backup system, functioning in case of the loss of telomerase activity, as demonstrated in yeast, human and plant telomerase mutants (Bryan et al. 1997; Lundblad and Blackburn 1993; Ruckova et al. 2008).”
BackgroundTelomerase-Independent Proliferation Is Influenced by Cell Type in Saccharomyces cerevisiae
Lowell, J. E., Roughton, A. I., Lundblad, V., & Pillus, L. (2003) · Genetics · doi:10.1093/genetics/164.3.909 · Cited by 23
Metzger, R., Vallböhmer, D., Müller‐Tidow, C., Higashi, H., Bollschweiler, E., Warnecke‐Eberz, U., Brabender, J., Baldus, S. E., Xi, H., Berdel, W. E., et al. (2009) · PubMed · Cited by 22
Johnson, J. E., Gettings, E. J., Schwalm, J., Pei, J., Testa, J. R., Litwin, S., von Mehren, M., & Broccoli, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1133 · Cited by 25
The MUS81 endonuclease is essential for telomerase negative cell proliferation
Zeng, S., & Yang, Q. (2009) · Cell Cycle · doi:10.4161/cc.8.14.9149 · Cited by 23
Regulation of snoRNAs in Cancer: Close Encounters with Interferon
Nallar, S. C., & Kalvakolanu, D. V. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0106 · Cited by 24
Targeting critical steps of cancer metastasis and recurrence using telomerase template antagonists
Dikmen, Z. G., Özgürtaş, T., Gryaznov, S. M., & Herbert, B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.01.018 · Cited by 23
“15%) use an alternative recombination-based mechanism termed ALT (alternative telomere lengthening) pathway [10].”
BackgroundFleisig, H. B., & Wong, J. M. Y. (2011) · Oncogene · doi:10.1038/onc.2011.292 · Cited by 23
“In contrast, a small proportion of human tumors utilize the alternate lengthening of telomere (ALT) mechanism, a non-physiological, homologous recombination-based system to maintain telomeres (Bryan et al., 1995, 1997).”
BackgroundNewhart, A., Rafalska-Metcalf, I. U., Yang, T., Joo, L. M., Powers, S. L., Kossenkov, A. V., Lopez-Jones, M., Singer, R. H., Showe, L. C., Skordalakes, E., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.473181 · Cited by 21
The telomerase challenge — an unusual problem in drug discovery
Pitts, A. E., & Corey, D. R. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01322-7 · Cited by 24
Telomere maintenance in sarcomas
Johnson, J. E., & Broccoli, D. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3281214423 · Cited by 22
Pitfalls in TRAP assay in routine detection of malignancy in effusions
Braunschweig, R., Guilleret, I., Delacrétaz, F., Bosman, F. T., Mihaescu, A., & Benhattar, J. (2001) · Diagnostic Cytopathology · doi:10.1002/dc.2043 · Cited by 21
POLA network, Grandin, N., Pereira, B., Cohen, C., Billard, P., Dehais, C., Carpentier, C., Idbaïh, A., Bielle, F., Ducray, F., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0833-0 · Cited by 21
Liu, J., Zheng, R., Zhang, Y., Jia, S., He, Y., & Liu, J. (2023) · Cancers · doi:10.3390/cancers15092640 · Cited by 24
FANCM branchpoint translocase: Master of traverse, reverse and adverse DNA repair
Abbouche, L., Bythell‐Douglas, R., & Deans, A. J. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103701 · Cited by 21
Topoisomerase II inhibition suppresses the proliferation of telomerase-negative cancers
Hsieh, M., Tsai, C.-H., Lin, C., Li, T., Hung, T.-W., Chang, L.-T., Hsin, L., & Teng, S. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1783-0 · Cited by 20
O’Hare, T. H., & Delany, M. E. (2011) · Cytogenetic and Genome Research · doi:10.1159/000330125 · Cited by 20
Molecular Genetics of Pancreatic Neoplasms
Hosoda, W., & Wood, L. D. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.05.011 · Cited by 21
Adult‐onset neuroblastoma: Report of seven cases with molecular genetic characterization
Duan, K., Dickson, B. C., Marrano, P. M., Thorner, P. S., & Chung, C. T. ‐. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22826 · Cited by 20
Gomes, N. M. V., Shay, J. W., & Wright, W. E. (2009) · Springer eBooks · doi:10.1007/978-90-481-3465-6_11 · Cited by 20
Telomere Biology of Pediatric Cancer
Tabori, U. Y., & Dome, J. S. (2007) · Cancer Investigation · doi:10.1080/07357900701208683 · Cited by 22
Tiptoeing to chromosome tips: facts, promises and perils of today's human telomere biology
Fajkus, J., Šimíčková, M., & Maláska, J. (2002) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2001.1053 · Cited by 20
“In human cells, telomerase-independent telomere maintenance (ALT) was observed in a minor fraction of telomerase-negative in vitro immortalized and tumourderived cell lines (Bryan et al. 1997).”
BackgroundKnockdown of Telomerase RNA Using Hammerhead Ribozymes and RNA Interference
Li, S., Nosrati, M., & Kashani–Sabet, M. (2007) · Methods in molecular biology · doi:10.1007/978-1-60327-070-0_10 · Cited by 20
Telomerase in hematologic malignancies
Bruedigam, C., & Lane, S. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000252 · Cited by 22
Carrillo, J., Calvete, O., Pintado‐Berninches, L., Manguán-García, C., Sevilla, J., Arias‐Salgado, E. G., Sastre, L., Güenechea, G., Granados, E. L., de Villartay, J., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx098 · Cited by 20
“Other manuscripts used U2OS cells that are known to maintain telomere length by the ALT pathway independently of telomerase activity (46).”
Molecular genetics of pineal region neoplasms
Taylor, M. D., Mainprize, T. G., Squire, J. A., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012713506549 · Cited by 22
Different telomere maintenance mechanisms in alveolar and embryonal rhabdomyosarcoma
Ohali, A., Avigad, S., Naumov, I., Goshen, Y., Ash, S., & Yaniv, I. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20600 · Cited by 20
“Although the majority of human epithelial tumors use telomerase for the constitutive maintenance of the telomeres, a subset of tumors employ a different mechanism called ALT (Alternative Lengthening of Telomeres), which may result from homologous recombination between telomeres, independent of telomerase (Bryan et al.…”
BackgroundPML nuclear bodies and their spatial relationships in the mammalian cell nucleus
Batty, E. (2009) · Frontiers in bioscience · doi:10.2741/3302 · Cited by 20
“To overcome this problem, certain immortalized cell lines are able to maintain, or even extend, telomeres via a homologous recombination (66, 67) that does not require telomerase.”
BackgroundAging and immortality in a cell proliferation model
Antal, T., Blagoev, K. B., Trugman, S. A., & Redner, S. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2007.06.009 · Cited by 20
Hsu, C. P., Miaw, J., Shai, S., & Chen, C. Y. (2004) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2004.04.029 · Cited by 21
“Similarly, immortalized cell lines and more than 80% of the cancer cells can prevent the telomere from progressive shortening by up-regulation of telomerase, whereas the remainder maintains telomeres by a alternative lengthening of telomeres (ALT) mechanism [5].”
BackgroundSiddiqa, A., Cavazos, D., & Marciniak, R. A. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.378 · Cited by 20
“A typical human ALT cell is characterized as possessing an indefinite replicative capacity by maintaining its telomere length despite 52 neuroepithelial origin (astrocytomas) or mesenchymal origin (osteosarcomas and soft tissue sarcomas).”
Expression of hTERT and hTR in cis reconstitutes an active human telomerase ribonucleoprotein
Bachand, F., Kukolj, G., & Autexier, C. (2000) · RNA · doi:10.1017/s1355838200000261 · Cited by 22
Differentiation Genes: Are They Primary Targets for Human Carcinogenesis?
Prasad, K. N., Hovland, A. R., Nahreini, P., Cole, W. C., Hovland, P., Kumar, B., & Prasad, K. C. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122600901 · Cited by 22
Appin, C., Hong, C., Suwala, A. K., Hilz, S., Mathur, R., Solomon, D. A., Smirnov, I. V., Stevers, N. O., Shai, A., Wang, A., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad231 · Cited by 19
Merlino, F., Marzano, S., Zizza, P., D’Aria, F., Grasso, N., Carachino, A., Iachettini, S., Biroccio, A., Fonzo, S. D., Grieco, P., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae471 · Cited by 21
“Of note, U2OS belong to a subcategory of tumour cells (accounting for about the 15% of total cancers), characterized by the capability to maintain telomeres length independently from telomerase activity ( 62 ,63 ).”
BackgroundVidaurreta, M., Maestro, M.-L., Rafael, S., Veganzones, S., Sanz-Casla, M.-T., Cerdán, J., & Arroyo, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i28.3868 · Cited by 20
Donaires, F. S., Alves‐Paiva, R. M., Gutierrez‐Rodrigues, F., da Silva, F. B., Tellechea, M. F., Moreira, L. F., Santana, B. A., Traina, F., Dunbar, C. E., Winkler, T., et al. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101540 · Cited by 20
“These mechanisms are based on homologous recombination-mediated DNA replication (Bryan et al., 1997; Dunham et al., 2000) and may play a role in telomere maintenance in the iPSCs.”
BackgroundSLX4IP and telomere dynamics dictate breast cancer metastasis and therapeutic responsiveness
Robinson, N. J., Morrison-Smith, C. D., Gooding, A. J., Schiemann, B. J., Jackson, M. W., Taylor, D. J., & Schiemann, W. P. (2020) · Life Science Alliance · doi:10.26508/lsa.201900427 · Cited by 20
“Although telomerase is believed to be the dominant TMM in many cancers, telomeres may also be extended via the homologous recombination-based ALT pathway (Bryan et al, 1997).”
The Role of Sumoylation in Senescence
Scurr, L. L., Haferkamp, S., & Rizos, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-50044-7_13 · Cited by 22
“Cancer cells overcome telomere shortening by either activating telomerase, the enzyme that synthesises new telomeric repeats or by activating homologous recombination mechanisms for lengthening telomeres, known as ALT (alternative lengthening of telomeres) ( Bryan et al., 1997; Shay, 1997).”
BackgroundPharmacodynamics of Telomerase Inhibition and Telomere Shortening by Noncytotoxic Suramin
Gan, Y., Lu, J. L., Yeung, B. Z., Cottage, C. T., Wientjes, M. G., & Au, J. L. ‐. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9703-7 · Cited by 19
“The effect of suramin on telomere length in cultured cells was studied in FaDu and PC3 cells that depend on telomerase for telomere maintenance and the telomerase-negative Saos-2 cells that do not depend on telomerase for telomere maintenance [42].”
BackgroundTPE or not TPE? It's no longer a question
Wood, J. G., & Sinclair, D. A. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01891-5 · Cited by 19
Jansen‐Dürr, P. (1998) · Experimental Gerontology · doi:10.1016/s0531-5565(98)00006-0 · Cited by 19
Anticancer Therapy Targeting Telomeres and Telomerase: Current Status
Parkinson, E. K., & Minty, F. (2007) · BioDrugs · doi:10.2165/00063030-200721060-00005 · Cited by 22
Martin, J. A., Forest, E. E., Block, J. A., Klingelhutz, A. J., Whited, B. W., Gitelis, S., Wilkey, A. L., & Buckwalter, J. A. (2002) · PubMed · Cited by 21
Characterization of Human Myocardial Fibroblasts Immortalized by HPV16 E6–E7 Genes
Harms, W., Rothämel, T., Miller, K., Harste, G., Grassmann, M., & Heim, A. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5274 · Cited by 19
Telomeres, Telomerase, Stress, and Aging
Lin, J., Epel, E. S., & Blackburn, E. H. (2009) · Wiley eBooks · doi:10.1002/9780470478509.neubb002065 · Cited by 21
Extrachromosomal telomere DNA derived from excessive strand displacements
Lee, J., Lee, J., Sohn, E. J., Taglialatela, A., O’Sullivan, R. J., Ciccia, A., & Min, J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318438121 · Cited by 23
Non-erythroid alpha spectrin prevents telomere dysfunction after DNA interstrand cross-link damage
Zhang, P., Herbig, U., Coffman, F. D., & Lambert, M. W. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt235 · Cited by 18
Pham, H. H., Murphy, C. T., Sureshkumar, G., Ly, D. H., Opresko, P. L., & Armitage, B. A. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00953c · Cited by 20
Lee, S., Borah, S., & Bahrami, A. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.01.003 · Cited by 18
Molecular Recognition of the Hybrid-Type G-Quadruplexes in Human Telomeres
Wu, G., Chen, L., Liu, W., & Yang, D. (2019) · Molecules · doi:10.3390/molecules24081578 · Cited by 20
How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
Akter, J., & Kamijo, T. (2021) · Biomolecules · doi:10.3390/biom11081112 · Cited by 21
To Fix or Not to Fix: Maintenance of Chromosome Ends Versus Repair of DNA Double-Strand Breaks
Casari, E., Gnugnoli, M., Rinaldi, C., Pizzul, P., Colombo, C. V., Bonetti, D., & Longhese, M. P. (2022) · Cells · doi:10.3390/cells11203224 · Cited by 22
“ALT mechanisms that depend on homologous recombination can be observed also in human telomerase-negative immortalized cell lines and in 10–15% of human cancers, which use them to re-elongate their telomeres and gain unlimited proliferative potential [179,180].”
BackgroundTelomerase as a novel and potentially selective target for cancer chemotherapy
Parkinson, E. K. (2003) · Annals of Medicine · doi:10.1080/07853890310006361 · Cited by 19
Telomere shortening triggers a feedback loop to enhance end protection
Yang, C.-W., Tseng, S., Yu, C., Chung, C., Chang, C.-Y., Pobiega, S., & Teng, S. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx503 · Cited by 21
Ferreira, M. S. V., Crysandt, M. M., Braunschweig, T. A., Jost, E., Voss, B., Bouillon, A., Knuechel, R., Brümmendorf, T. H., & Beier, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020608 · Cited by 20
“A glioblastoma sample was included as positive control for the presence of ALT.”
BackgroundInfluentialTelomeres in Drag: dressing as DNA damage to engage telomerase
Rog, O., & Cooper, J. P. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.011 · Cited by 22
Matsuo, T., Shimose, S., Kubo, T., Fujimori, J., Yasunaga, Y., & Ochi, M. (2010) · PubMed · Cited by 18
Kim, J. H., Lee, G. E., Kim, J. C., Lee, J. H., & Chung, I. K. (2002) · Molecules and Cells · doi:10.1016/s1016-8478(23)15027-8 · Cited by 20
Telomerase: Not Just Black and White, but Shades of Gray
Liu, J. (2000) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.2000.0203 · Cited by 20
Smith, S. K., & Kipling, D. (2004) · Cytogenetic and Genome Research · doi:10.1159/000078219 · Cited by 22
“…stabilization appears to be a key event in acquisition of the immortal phenotype, since the majority of human tumours lose the repression of telomerase activity, or maintain the length of their telomeres by an alternative, recombination-based mechanism (Kim et al., 1994; Bryan et al., 1997).”
BackgroundChen, W., He, L., Liang, Y., Zeng, X. G., Wu, C., Su, M., Yang, C., & Liu, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11623 · Cited by 18
“In total, >90% of human cancers have been discovered to abnormally express telomerase (28), while tumors that do not express telomerase are based on recombination between telomere sequences and activating another extension (29).”
BackgroundMaï, M. E., Hreich, S. J. D., Gaggioli, C., Roisin, A., Wagner, N., Ye, J., Jalinot, P., Cherfils‐Vicini, J., & Gilson, É. (2021) · Cancers · doi:10.3390/cancers13122998 · Cited by 18
“This lag period reduces therapeutic efficacy and increases pro-aging side effects by limiting cell renewal and favoring the activation of alternative recombination-based telomere elongation mechanisms [9,10].”
BackgroundGenetic and epigenetic trends in telomere research: a novel way in immunoepigenetics
Melicher, D., Buzás, E. I., & Falus, A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1991-2 · Cited by 19
Telomeres and telomerase in normal and malignant B‐cells
Lobetti‐Bodoni, C., Bernocco, E., Genuardi, E., Boccadoro, M., & Ladetto, M. (2010) · Hematological Oncology · doi:10.1002/hon.937 · Cited by 18
Altered States of Telomere Deprotection and the Two-Stage Mechanism of Replicative Aging
Zou, Y. S., Misri, S., Shay, J. W., Pandita, T. K., & Wright, W. E. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01569-08 · Cited by 20
“ALT (alternative lengthening of telomeres) pathway (4, 5),”
BackgroundWang, L., Wang, L., Mao, L., Spitz, M. R., & Wei, Q. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0269 · Cited by 18
“Similarly, hTERT expression is also detectable in approximately 85% of NSCLC tissues, and the remaining small telomerase-negative minority maintain their telomeres by an alternative lengthening of telomeres mechanism (24).”
Transient Telomerase Inhibition with Imetelstat Impacts DNA Damage Signals and Cell-Cycle Kinetics
Thompson, C. A. H., Gu, A. P., Yang, S. Y. C., Mathew, V., Fleisig, H. B., & Wong, J. M. Y. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0772 · Cited by 19
Venturini, L., Erdas, R., da Costa, A. C., Gronchi, A., Pilotti, S., Zaffaroni, N., & Daidone, M. G. (2007) · The Journal of Pathology · doi:10.1002/path.2288 · Cited by 17
“In some tumours of mesenchymal origin, telomere length is also maintained by one or more mechanisms referred to as alternative lengthening of telomeres (ALT) [2].”
BackgroundTelomeres and telomerase in adrenocortical tissue maintenance, carcinogenesis, and aging
Else, T. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0189 · Cited by 21
“Following www.endocrinology-journals.org the description of this phenomenon, a few malignant tumor entities emerged that did not display any considerable TA, but yet did not undergo crisis or progressed to senescence (Bryan et al. 1997).”
BackgroundInfluentialInduction of Global Stress Response in Saccharomyces cerevisiae Cells Lacking Telomerase
Teng, S., Epstein, C. B., Tsai, Y.-L., Cheng, H.-W., Chen, H.-L., & Lin, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6509 · Cited by 18
Mitogenic factors accelerate later-age diseases: insulin as a paradigm
Lev-Ran, A. (1998) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00027-x · Cited by 18
Can a single model explain both breast cancer and prostate cancer?
Friedman, A. (2007) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-4-28 · Cited by 17
Hyperextended telomeres promote formation of C-circle DNA in telomerase positive human cells
Jones, C. Y., Williams, C. L., Moreno, S. P., Morris, D. K., Mondello, C., Karlseder, J., & Bertuch, A. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104665 · Cited by 16
Lu, R., Nelson, C. B., Rogers, S., Cesare, A. J., Sobinoff, A. P., & Pickett, H. A. (2023) · iScience · doi:10.1016/j.isci.2023.108655 · Cited by 17
Identification of modulators of the ALT pathway through a native FISH-based optical screen
Azeroglu, B., Khurana, S., Wang, S.-C., Tricola, G. M., Sharma, S., Jubelin, C., Cortolezzis, Y., Pegoraro, G., Miller, K. M., Stracker, T. H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115114 · Cited by 17
“5,6 Major advances in understanding the ALT pathway have been made in recent years (reviewed in Bhargava et al., 7 Claude and Decottignies, 8 and Loe et al. 9 ).”
PML Nuclear Bodies and Other Trim-Defined Subcellular Compartments
Batty, E., Jensen, K., & Freemont, P. S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5398-7_4 · Cited by 18
How stem cells keep telomeres in check
Li, J. S. Z., & Denchi, E. L. (2018) · Differentiation · doi:10.1016/j.diff.2018.01.004 · Cited by 18
“Telomeres can also be extended in a telomerase-independent manner by a recombination-based process termed alternative lengthening of telomeres (ALT) (Bryan et al., 1997) (Fig.”
Molecular Mechanism of Telomere Length Dynamics and Its Prognostic Value in Pediatric Cancers
Wang, Z., Rice, S. V., Chang, T., Liu, Y., Liu, Q., Qin, N., Putnam, D. K., Shelton, K., Lanctot, J. Q., Wilson, C. L., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz210 · Cited by 18
“In cancer cells, telomere shortening can be reversed by activation of telomerase (TERT) (3–5) and/or the alternative lengthening of telomere (ALT) mechanism (6,7), thus A R T IC LE”
BackgroundKent, T., & Clynes, D. (2021) · Genes · doi:10.3390/genes12111734 · Cited by 16
“A minority of cancers, the so-called ALT cancers, have established telomerase-independent mechanisms of telomere elongation [21].”
BackgroundDisrupting Mechanisms that Regulate Genomic Repeat Elements to Combat Cancer and Drug Resistance
Kermi, C., Lau, L., Shahmirzadi, A. A., & Classon, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.826461 · Cited by 16
Argilla, D., Chin, K., Singh, M., Hodgson, J. G., Bosenberg, M., Ortíz-de-Solórzano, C., Lockett, S. J., DePinho, R. A., Gray, J. W., & Hanahan, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.032 · Cited by 19
Comprehensive Nanorobotic Control of Human Morbidity and Aging
Freitas, R. A. (2010) · The Future of Aging · doi:10.1007/978-90-481-3999-6_23 · Cited by 16
“ening telomeres (Bryan et al. 1997)) from all cells that are able to divide.”
BackgroundWang, H., Wang, Y., Kota, K. K., Kallakury, B., Mikhail, N. N. H., Sayed, D. M., Mokhtar, A., Maximous, D., Yassin, E. H., Gouda, I., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv121 · Cited by 17
“However, almost all cancer cells have found ways to escape from the normal replicative limitation through maintaining their telomeres, either by upregulation of telomerase (11) or by an alternative lengthening of telomeres (ALT) mechanism (12,13).”
BackgroundTelomerase Activity in Cell Lines of Pediatric Soft Tissue Sarcomas
Kleideiter, E., Schwab, M. G., Friedrich, U. A., Kościelniak, E., Schäfer, B. W., & Klotz, U. E. (2003) · Pediatric Research · doi:10.1203/01.pdr.0000086901.29111.2a · Cited by 16
“This indicates that cell lines represent suitable systems to imitate the biologic behavior of tumor cells in vivo (39).”
BackgroundResultTelomerase activity in human renal cell carcinoma
Sugimura, Yoshida, Hisatomi, Nakatani, & Ikemoto (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00992.x · Cited by 17
Nickles, K., & McEachern, M. J. (2004) · Yeast · doi:10.1002/yea.1119 · Cited by 16
“This process has been observed in the absence of telomerase activity in human cell lines (Bryan et al., 1997; Dunham et al., 2000) as well as in S. cerevisiae (Lundblad and Blackburn, 1993; Teng and Zakian, 1999) and K. lactis yeast mutants lacking telomerase (McEachern and Blackburn, 1996).”
BackgroundMethodMouse models to study the role of telomeres in cancer, aging and DNA repair
Blasco, M. A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00450-1 · Cited by 18
Tetrahymena Mutants With Short Telomeres
Ahmed, S. C., Hong, S., Niu, L., & Henderson, E. R. (1998) · Genetics · doi:10.1093/genetics/150.2.643 · Cited by 16
Tsutsui, T. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg024 · Cited by 19
“All of telomerase-negative cell lines derived from human tumors and the small proportion of human tumors that are negative for telomerase activity also maintain very long TRF lengths (9, 31 ).”
BackgroundSignalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)
Kusuma, F. K., Prabhu, A., Tieo, G., Ahmed, S. M., Dakle, P., Yong, W. K., Pathak, E., Madan, V., Jiang, Y. Y., Tam, W. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37633-3 · Cited by 17
Porika, M., Tippani, R., & Saretzki, G. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063002 · Cited by 17
“The tumors can still grow without TA because they maintain telomeres and avoid senescence with an alternative lengthening of telomeres (ALT) mechanism which is based on homologous recombination of telomeres [81,82].”
BackgroundSumida, T., & Hamakawa, H. (2001) · Oral Oncology · doi:10.1016/s1368-8375(00)00132-9 · Cited by 18
Telomere uncapping at the crossroad between cell cycle arrest and carcinogenesis
Gobbini, E., Trovesi, C., Cassani, C., & Longhese, M. P. (2014) · Molecular & Cellular Oncology · doi:10.4161/mco.29901 · Cited by 17
“Most human cancers maintain their telomeres through reactivation of telomerase but on rare occasions telomeres can be elongated through a homologous recombination-mediated process called alternative lengthening of telomeres (ALT).(76) The existence of a telomerase-independent telomere maintenance mechanism was first d…”
BackgroundTelomerase as a new target for pancreatic cancer treatment
Sato, N., Mizumoto, K., Nagai, E., & Tanaka, M. (2002) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340200036 · Cited by 16
Modeling growth and telomere dynamics in Saccharomyces cerevisiae
Olofsson, P., & Bertuch, A. A. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.12.004 · Cited by 15
Telomeres and telomerase in sarcomas.
Matsuo, T., Shimose, S., Kubo, T., Fujimori, J., Yasunaga, Y., & Ochi, M. (2009) · PubMed · Cited by 15
Dynamics of telomeric chromatin at the crossroads of aging and cancer
Ye, J., Wu, Y., & Gilson, É. (2010) · Essays in Biochemistry · doi:10.1042/bse0480147 · Cited by 17
“shelterin subunits) contribute to oncogenesis, and telomerase-independent pathways may maintain telomere length in tumour cells [43].”
BackgroundMethod
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.